Skip to Main Content

Author Details

Fred Saad
University of Montreal Health Center
1990
873
91
PMIDPaper TitleJournal TitlePublished Year
37344282Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy.Clin Genitourin Cancer2024
37690970Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites.Clin Genitourin Cancer2024
35197558Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.Prostate Cancer Prostatic Dis2023
37714168Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.Lancet Oncol2023
37558516Conditional survival of stage III non-seminoma testis cancer patients.Urol Oncol2023
37483849The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer.Cent European J Urol2023
378519132023 Canadian Urological Association guideline: Genetic testing in prostate cancer.Can Urol Assoc J2023
37620428Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.Prostate Cancer Prostatic Dis2023
37585665Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?Future Oncol2023
37787591Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries.Can Urol Assoc J2023
37506474Regional differences in penile cancer patient characteristics and treatment rates across the United States.Cancer Epidemiol2023
37640983Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls.Int Urol Nephrol2023
37494316Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional survey.Can Urol Assoc J2023
37672815The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.Eur J Cancer2023
37530661Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries.Minerva Urol Nephrol2023
35790787Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer.Prostate Cancer Prostatic Dis2023
35750582Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.Eur Urol2023
37221827Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence.Minerva Urol Nephrol2023
37024421Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients.Eur Urol Focus2023
37288965Exercise Mediates Myokine Release and Tumor Suppression in Prostate Cancer Independent of Androgen Signaling.Exerc Sport Sci Rev2023
36948042Regional differences in total hospital costs for radical cystectomy in the United States.Surg Oncol2023
37251627Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer.EClinicalMedicine2023
37150260Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial.Int J Radiat Oncol Biol Phys2023
37046815Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma.Cancers (Basel)2023
36984452Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages.Medicina (Kaunas)2023
37043366African American vs Caucasian race/ethnicity in adrenocortical carcinoma patients.Endocr Relat Cancer2023
37040594External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.J Clin Oncol2023
37441347Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma.Eur Urol Open Sci2023
37141747Conditional survival for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder after radical cystectomy.Surg Oncol2023
37404070Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.J Manag Care Spec Pharm2023
37071764Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer.Prostate2023
37003085Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.Eur J Cancer2023
37365054Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion.Clin Genitourin Cancer2023
37062659Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.Clin Genitourin Cancer2023
36446945Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer.Prostate Cancer Prostatic Dis2023
36882338Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer.Urol Oncol2023
36813873Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities.Int Urol Nephrol2023
36919872The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy.Prostate2023
36401949Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma.Cancer Epidemiol2023
36473471The effect of chemotherapy in sarcomatoid bladder cancer patients treated with radical cystectomy.Can Urol Assoc J2023
36612319Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?Cancers (Basel)2023
36434748Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis.J Surg Oncol2023
36640918Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States.Ann Epidemiol2023
36428165Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis.Urol Oncol2023
36831589Editorial for the Special Edition of Advanced Prostate Cancer: From Bench to Bedside.Cancers (Basel)2023
36639035PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial.Int J Radiat Oncol Biol Phys2023
36906483The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ⿤4 cm.Eur Urol Focus2023
36902562The Effect of Sex on Disease Stage and Survival after Radical Cystectomy in Non-Urothelial Variant-Histology Bladder Cancer.J Clin Med2023
36765653Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages.Cancers (Basel)2023
36899091Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.Prostate Cancer Prostatic Dis2023
  • 1 - 50 of 873

Recommended Authors

Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 18
Adam B Weiner
Northwestern University Feinberg School of Medicine
Career Start Year 2013
Number of shared co-authors 20
Devin N Patel
university of california san diego School of Medicine
Career Start Year 2011
Number of shared co-authors 6
Izak Faiena
Columbia University Medical Center
Career Start Year 2010
Number of shared co-authors 3
Alastair D Lamb
University of Oxford
Career Start Year 2007
Number of shared co-authors 29
Jonathan L Wright
University of Washington Medical Center
Career Start Year 2005
Number of shared co-authors 24
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 25
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Career Start Year 2004
Number of shared co-authors 69
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 63
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 24
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Career Start Year 2003
Number of shared co-authors 40
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 39
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 18
Robert Jeffrey Karnes
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 75
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 51
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 53
Vincent J Gnanapragasam
University of Cambridge
Career Start Year 1999
Number of shared co-authors 14
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 17
Wolfgang Lilleby
Oslo University Hospital
Career Start Year 1999
Number of shared co-authors 16
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 29
Todd M Morgan
University of Michigan ann arbor
Career Start Year 1997
Number of shared co-authors 55
Niall M Corcoran
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1997
Number of shared co-authors 22
Phuoc T Tran
University of Maryland School of Medicine
Career Start Year 1996
Number of shared co-authors 57
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 27
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 35
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 46
Philip Cornford
Liverpool University Hospitals
Career Start Year 1988
Number of shared co-authors 16
Alan W Partin
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1987
Number of shared co-authors 41
Freddie C Hamdy
University of Oxford
Career Start Year 1987
Number of shared co-authors 44
Ian M Thompson
CHRISTUS Santa Rosa Hospital-Medical Center
Career Start Year 1956
Number of shared co-authors 47

Collaborators

Alberto Briganti
IRCCS San Raffaele Scientific Institute
Co-authored papers 235
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Co-authored papers 155
Derya Tilki
Universitatsklinikum Hamburg-Eppendorf
Co-authored papers 134
Cora N Sternberg
Meyer Cancer Center, Englander Institute for Precision Medicine
Co-authored papers 47
Kim N Chi
University of British Columbia
Co-authored papers 47
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 41
Armen Aprikian
McGill University Health Centre, McGill University
Co-authored papers 35
Martin E Gleave
University of British Columbia
Co-authored papers 34
Giorgio Gandaglia
IRCCS San Raffaele Scientific Institute, Italy Vita-Salute San Raffaele University
Co-authored papers 33
Louis Lacombe
CHU de Quebec-Universite Laval
Co-authored papers 32
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 30
Yves Fradet
CHU de Quebec-Universite Laval
Co-authored papers 29
Maha Hussain
Northwestern University
Co-authored papers 28
Eric J Small
University of California san francisco
Co-authored papers 26
Eleni Efstathiou
Houston Methodist Cancer Center
Co-authored papers 26
Joseph L Chin
University of Western Ontario
Co-authored papers 26
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 25
Neil E Fleshner
University of Toronto
Co-authored papers 23
Mathieu Latour
Centre Hospitalier de l'Universite de Montreal
Co-authored papers 22
Dominique Trudel
Institut du cancer de Montreal
Co-authored papers 21
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 21
Oliver Sartor
Tulane University School of Medicine
Co-authored papers 20
Hartwig Huland
Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf
Co-authored papers 18
Dana E Rathkopf
Memorial Sloan Kettering Cancer Center
Co-authored papers 18
Simone Chevalier
McGill University Health Centre, McGill University
Co-authored papers 16
Antonio Finelli
Princess Margaret Cancer Centre, University Health Network and University of Toronto
Co-authored papers 16
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 16
Jean-Simon Diallo
Ottawa Hospital Research Institute, University of Ottawa
Co-authored papers 12
Michael J Morris
Memorial Sloan Kettering Cancer Center
Co-authored papers 12
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 11
Release 1.2